Vimta Labs Achieves Record Q2 Revenue of INR 104.5 Crore, Driven by Pharma and Food Testing Services

Vimta Labs Limited (ISIN: INE579C01029) has reported its highest-ever quarterly sales revenue of INR 104.5 crore in Q2 FY26, marking a significant 22.3% year-on-year growth. The company's strong performance was primarily driven by its pharmaceutical research and testing services, as well as food testing services.

Financial Highlights

Metric	Q2 FY26	Q2 FY25	YoY Growth
Total Income	1,045.00	854.00	22.3%
EBITDA	369.00	306.00	20.6%
EBITDA Margin	35.3%	35.8%	-50 bps
Profit After Tax	199.00	170.00	17.1%
PAT Margin	19.1%	19.9%	-80 bps

All financial figures in INR million, except percentages

Key Business Segments

Vimta Labs' revenue mix for Q2 FY26 was as follows:

Pharmaceutical services: ~65% of total revenue
Food testing services: ~20% of total revenue
Environmental and electronics testing services: Remainder

Operational Highlights

The company's clinical research division successfully completed a WHO audit, reflecting its commitment to maintaining strong quality and compliance standards.
Vimta Labs has commenced operations with a new testing chamber installed at its life sciences facility, expanding capacity in the electrical and electronics division.
The company is progressing with its biologics contract research and development services project, with the facility expected to be ready by the end of Q3 FY26 and commercialization anticipated in Q1 FY27.

Expansion and Future Outlook

Vimta Labs has incurred a capex of INR 47 crore during the first half of FY26.
The company plans to spend approximately INR 25 crore on biologics expansion this year.
Management remains confident about achieving its targeted exit run rate of around INR 500 crore for the current financial year.

Market Position and Competition

Vimta Labs competes with both domestic and international players across its various service segments:

In food testing, competitors include multinational companies like SGS, Eurofins, Intertek, and Bureau Veritas.
For pharmaceutical services, the company faces competition from both domestic and international Contract Research Organizations (CROs).

The company's strategy involves expanding its global reach and integrating its services to provide end-to-end solutions, particularly in the growing biologics and large molecule research and development support services.

Vimta Labs maintains a strong balance sheet with no debt and cash and cash equivalents, including bank balances, of INR 545.00 million as of September 30, 2025.

As the pharmaceutical and food testing industries continue to grow, Vimta Labs is well-positioned to capitalize on emerging opportunities, supported by its expanded capacities and focus on technological advancements in testing methodologies.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.68%	-4.49%	-11.16%	+20.28%	+59.55%	+803.70%

Vimta Labs , a leading testing and research organization, has announced its financial results for the second quarter, showcasing robust growth across key metrics.

Financial Highlights

Metric	Q2 (Current Year)	Q2 (Previous Year)	Year-over-Year Change
Revenue	₹1,000.00 million	₹847.00 million	+18.1%
Net Profit	₹199.00 million	₹170.00 million	+17.1%
EBITDA	₹342.00 million	₹299.00 million	+14.4%
EBITDA Margin	34.20%	35.30%	-110 bps

Revenue Growth

Vimta Labs reported a significant increase in revenue for the second quarter, reaching ₹1,000.00 million, up from ₹847.00 million in the same period last year. This represents a strong year-over-year growth of 18.1%, indicating the company's ability to expand its business and capture market opportunities.

Profitability

The company's net profit also saw a notable improvement, rising to ₹199.00 million from ₹170.00 million in the corresponding quarter of the previous year. This 17.1% increase in net profit demonstrates Vimta Labs' ability to translate revenue growth into bottom-line results.

EBITDA Performance

Vimta Labs' EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew to ₹342.00 million, compared to ₹299.00 million in the prior year period, marking a 14.4% increase. This growth in EBITDA indicates improved operational efficiency and cost management.

Margin Analysis

Despite the overall positive performance, Vimta Labs experienced a slight decline in its EBITDA margin. The EBITDA margin for the quarter stood at 34.20%, down from 35.30% in the same period last year, representing a decrease of 110 basis points. This marginal contraction in margins may be attributed to factors such as increased operational costs or changes in the revenue mix.

The company's ability to maintain a healthy EBITDA margin above 34% while significantly growing its revenue demonstrates its operational resilience and efficient cost management in a potentially challenging business environment.

Conclusion

Vimta Labs' Q2 results reflect a company on a growth trajectory, with substantial improvements in revenue and profitability. The slight margin pressure suggests that the company may need to focus on optimizing its cost structure to fully capitalize on its revenue growth in future quarters.